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A Polymerase Chain Reaction/Ligase Detection Reaction–Fluorescent Microsphere
Assay to Determine Plasmodium falciparum MSP-119 Haplotypes
Arlene E. Dent, Christopher T. Yohn, Peter A. Zimmerman, John Vulule, James W. Kazura, and Ann M. Moormann*
Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio; Kenya Medical
Research Institute, Center for Vector Control and Biology Research, Kisumu, Kenya
Abstract. The merozoite surface protein-1 (MSP-1) is a blood stage antigen currently being tested as a vaccine
against Plasmodium falciparum malaria. Determining the MSP-119 haplotype(s) present during infection is essential for
assessments of MSP-1 vaccine efficacy and studies of protective immunity in human populations. The C-terminal
fragment (MSP-119) has four predominant haplotypes based on point mutations resulting in non-synonymous amino acid
changes: E-TSR (PNG-MAD20 type), E-KNG (Uganda-PA type), Q-KNG (Wellcome type), and Q-TSR (Indo type).
Current techniques using direct DNA sequencing are laborious and expensive. We present an MSP-119 allele-specific
polymerase chain reaction (PCR)/ligase detection reaction–fluorescent microsphere assay (LDR-FMA) that allows
simultaneous detection of the four predominant MSP-119 haplotypes with a sensitivity and specificity comparable with
other molecular methods and a semi-quantitative determination of haplotype contribution in mixed infections. Appli-
cation of this method is an inexpensive, accurate, and high-throughput alternative to distinguish the predominant
MSP-119 haplotypes in epidemiologic studies.
INTRODUCTION
Merozoite surface protein-1 (MSP-1) is the most abundant
protein found on the surface of blood stage Plasmodium fal-
ciparum (Pf) merozoites and is currently being tested as a
vaccine against Pf malaria. MSP-1 is expressed late in the
blood stage cycle as a ∼200-kd precursor protein attached to
the merozoite surface through a C-terminal glycosyl phos-
phatidylinositol (GPI) anchor. Full-length MSP-1 undergoes
primary proteolytic processing just before schizont rupture to
produce a complex of four MSP-1 fragments that remain non-
covalently associated on the merozoite surface.1 During
merozoite invasion of the erythrocyte, the MSP-142 fragment
that anchors the complex to the merozoite surface is further
processed to produce MSP-133 and MSP-119.
1–3 MSP-119 re-
mains on the merozoite surface during invasion and is readily
detectable in the newly infected erythrocytes.2 The MSP-1
gene can be divided into conserved, semi-conserved, and vari-
able blocks based on comparisons of deduced amino acid
sequences of various clones and field isolates.4 Block 17 en-
codes MSP-119 that includes 98 highly conserved amino acids
with the exception of residues 1644, 1691, 1700, and 1701.
Non-synonymous changes at these positions result in four
predominant haplotypes: E-TSR (PNG-MAD20 type), E-
KNG (Uganda-PA type), Q-KNG (Wellcome type), and Q-
TSR (Indo type).5–8
Antibodies directed against the conserved MSP-119–kDa C-
terminal region are associated with protection against malaria
infection or disease.9–12 It is unclear whether protective im-
mune responses are haplotype specific or if past exposure to
one haplotype conveys cross protection to another. Some
cross-protection has been shown in animal models13 but not
definitively in human studies. MSP-1 vaccines are currently in
clinical trials. To interpret immunologic endpoints for MSP-1
vaccines tested in malaria-endemic areas, it is important to
determine the MSP-119 haplotype variants within a popula-
tion and their influence on the development of MSP-119–
specific immunity. Traditionally, polymerase chain reaction
(PCR) amplification and DNA sequencing have been pre-
ferred methodologies to determine allelic prevalence in a
population. This method has been used to estimate the pro-
portions of alleles in mixed Pf infections when those differ-
ences were caused by single nucleotide polymorphisms; how-
ever, this method tends to be costly, does not lend itself to
high-throughput sample processing, and requires knowledge
of bioinformatics for accurate comparisons within large
datasets.14 Cloning multiple PCR amplicons from a single
individual can also be used to determine the proportion of
alleles in a mixed infection, but this is impractical on a large
scale with population-based studies. New methods that ex-
ploit targeted sequencing of specific genes can overcome la-
borious cloning.15 These methods are very precise, but expen-
sive and time consuming. Real-time quantitative PCR (RTQ-
PCR) has been used to determine Plasmodium parasite
density but amplifies a species-specific ribosomal subunit16,17
and is not successful at distinguishing allelic variants that dif-
fer by single nucleotide polymorphisms. Additionally, it is
limited to only a few allelic markers that can be differentiated
in a single multiplexed reaction.
Our goal was to develop a high-throughput, accurate, and
inexpensive method to determine the relative contribution of
each predominant MSP-119 haplotype within a mixed Pf
strain infection. We adapted a PCR-based ligase detection
reaction–fluorescent microsphere assay (LDR-FMA) method
to distinguish between the four predominant MSP-119 haplo-
types, their relative frequency within a population, and their
quantitative contribution to an individual sample within a
mixed infection. This method is particularly suited to monitor
Pf MSP-1 genetic diversity within and between human popu-
lations and will significantly contribute to understanding
MSP-1 vaccine intervention outcomes.
MATERIALS AND METHODS
Study population. Healthy individuals (101 adults and 100
children) from the malaria holoendemic sub-location of Kan-
yawegi, Kenya, were enrolled in July 2003 during a time of
relatively high malaria transmission. Adults were older than
18 years of age, and the average age of the children was 7.7
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years old. All study participants were afebrile and had normal
age-adjusted hemoglobin levels. Ethical approval for human
study was obtained from the Institutional Review Board at
Case Western Reserve University, University Hospital of
Cleveland, and the Ethical Review Committee at the Kenya
Medical Research Institute. Adults participating in this study
signed a written consent form in English or Duhluo (the local
language), and parents or guardians signed in the case of
minors.
Blood smear examination. Thick and thin blood smears
(BSs) were prepared, fixed in 100% methanol, stained with
5% Giemsa solution, and examined by light microscopy for P.
falciparum–infected erythrocytes. The density of parasitemia
was expressed as the number of asexual P. falciparum per
microliter of blood assuming a leukocyte count of 8,000/L.
DNA extraction. DNA was extracted from 200 L of
venous blood (collected in EDTA anti-coagulant) and para-
site cultures (3D7 and K1 strains) using QIAamp DNA blood
mini kit (Qiagen, Valencia, CA).
RTQ-PCR. Extracted DNA (2.5 L) was used as template
for amplification of the multicopy P. falciparum 18S small
subunit ribosomal (ssu) RNA gene by RTQ-PCR.17,18 Results
are reported as copies per microliter of blood.
MSP-119 DNA sequencing. Samples were sequenced from
MSP-119 PCR products using primers and conditions previ-
ously described.8 PCR products were purified using
QIAquick 96 PCR purification kit (Qiagen). DNA sequenc-
ing was performed by MGW Biotech (MGW Biotech, High
Point, NC).
MSP-119 and Pf rRNA PCR amplification. PCR primers
were synthesized8 to amplify a 376-bp region of MSP-119 con-
taining the point mutations of interest: upstream primer
5AACATTTCACAACACCAATGC-3 and downstream
primer 5TTAAGGTAACATATTTTAACTCCTAC-3 (In-
tegrated DNA Technologies, Coralville, IA). This set of
MSP-119 PCR primers was multiplexed with Pf-specific PCR
primers for ssu rRNA gene fragment as previously pub-
lished.19 Each PCR (25 L) contained 1× PCR buffer (Perkin-
Elmer, Norwalk, CT), 1.5 mmol/L MgCl, 200 mol/L dNTPs,
300 nmol/L of each primer, and 1.5 units of AmpliTaq DNA
polymerase (Perkin-Elmer), to which 1 L sample DNA was
added. Cycling conditions were as follows: 94°C for 30 sec-
onds, 55°C for 30 seconds, and 63°C for 2 minutes for 35
cycles, followed by a final extension at 63°C for 7 minutes. A
3-L aliquot was removed from each reaction at 27 cycles
during optimal non-saturated PCR cycling. Twenty-seven-
cycle PCR aliquots were used for the semi-quantitative de-
termination of MSP-119 allele and Pf infection levels.
19 LDR-
FMA using 35-cycle PCR products were used to determine
the presence of MSP-119 alleles and detect Pf infection in
samples. PCR products were subjected to electrophoresis on
2% agarose gels, stained with SYBR Gold (Molecular Probes,
Eugene, OR), and visualized on a Storm 860 using Im-
ageQuant, 5.2 software (Molecular Dynamics, Sunnyvale,
CA).
LDR-FMA. The LDR-FMA was adapted to distinguish be-
tween single nucleotide polymorphisms that recognize G ver-
sus A corresponding to amino acid position 1644 (E versus Q
variant), and GCA versus ACG (position 1699–1701) corre-
sponding to the last two nucleotide bases of S and N codons
and the first base of the R and G codons, respectively.8 Four
allele-specific probes and two fluorescently labeled conserved
sequence probes were designed (Table 1). Additionally, a
Plasmodium-specific fluorescently labeled conserved probe
(designated “Common1”) and a Pf specific probe (designated
“Pf1”) previously described were included in the LDR-FMA
reaction.19 In total, five specific probes (four MSP-119–allele
specific and one Pf-specific) and three conserved sequence
probes were included in the multiplexed detection reaction.
To one LDR reaction, 1 L of the PCR reaction was added
(either from the 27-cycle or 35-cycle PCR product aliquot).
The LDR reaction was performed with 1 L of the PCR
reaction, 10 nmol/L (200 fmol) of each probe, and 2 units of
Taq DNA ligase (New England Biolabs, Beverly, MA) in a
buffer containing 20 mmol/L Tris-HCl buffer, pH 7.6, 25
mmol/L potassium acetate, 10 mmol/L magnesium acetate, 1
mmol/L NAD+, 10 mmol/L dithiothreitol, and 0.1% Triton
X-100. LDR reactions (total volume 15 L) were heated to
95°C for 1 minute, followed by 32 thermal cycles at 95°C for
15 seconds and 58°C for 2 minutes. Five microliters of the
multiplexed LDR reaction was added to 60 L of hybridiza-
tion solution: 3 mol/L tetramethylammonium chloride
(TMAC), 50 mmol/L Tris-HCl, pH 8.0, 3 mmol/L EDTA, pH
8.0, and 0.1% sodium dodecyl sulfate, containing 250 Lu-
minex FlexMAP microspheres from each allelic set (total
number  5). The hybridization reactions were heated to
95°C for 90 seconds and incubated at 37°C for 40 minutes to
allow hybridization between allele-specific LDR products and
microsphere-labeled anti-TAG probes. After hybridization, 6
L of streptavidin-R-phycoerythrin (Molecular Probes) in
TMAC hybridization solution (20 ng/L) was added to the
hybridization reaction and incubated at 37°C for 40 minutes
in Costar-6511M polycarbonate 96-well V-bottom plates
(Corning, Corning, NY).19,20 Detection of allele-specific
TABLE 1












Nucleotides in lowercase represent the TAG sequences added to the 5’ end of each allele-specific LDR primer. Nucleotides in bold represent differences between the differentiated alleles (Q
vs. E and KNG vs. TSR).
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LDR:microsphere-labeled anti-TAG hybrid complexes was
performed using a BioPlex array reader (Bio-Rad Laborato-
ries, Hercules, CA).19 Each Luminex fluorescent microsphere
emits a unique fluorescent “classification” signal across the
range of 658–712 nm. “Reporter” fluorescent signals from
R-phycoerythrin are detected, classified into the allele-
specific bins, and reported as median fluorescent intensity
(MFI) by the BioPlex array reader and BioPlex Manager 3.0
software.
RESULTS
MSP-119 PCR/LDR-FMA determined allele specificity.
MSP-119–allele specific determination was conducted using
PCR products generated after 35 PCR cycles when saturated
cycling occurs. Each Luminex fluorescent microsphere has
105–106 anti-TAG oligos per bead. Thus, the maximal fluo-
rescent signal associated with each microsphere must be as-
certained. Determining positive threshold cut-off values was
established for each allele-specific microsphere using DNA
isolated from cultured Pf strains 3D7 (E-TSR haplotype) and
K1 (Q-KNG haplotype). Parasite DNA was combined in a 1:1
ratio and serially diluted. Figure 1 shows the average MFIs for
each allele at each dilution for 16 separate MSP-119 PCR/
LDR-MFA experiments to determine each microsphere
threshold value.20 Fluorescence cut-off values for micro-
spheres associated with “Q” and “E” were set at an MFI of
800, and cut-off values for microspheres associated with
“KNG” and “TSR” were set at an MFI of 3,000. The cut-off
values for the microsphere associated with “Pf” was set at an
MFI of 3,000. Thresholds for MSP-119 allele or Pf detection
did not change when experiments were performed with back-
ground human DNA added to cultured parasite DNA (data
not shown).
Sensitivity and specificity of MSP-119 allele-specific PCR/
LDR-FMA compared with sequencing. Sixty-one Pf PCR-
positive (56 BS positive) Kenyan samples were sequenced
using traditional direct sequencing and compared with PCR/
LDR-FMA. In a single sample, multiple alleles may be
present; each sample has the potential to have all four alleles
present. Therefore, 244 alleles (61 × 4) had to be determined.
Each allele (Q, E, KNG, and TSR) was therefore assessed
independently for each sample. As an example, sequencing a
single sample may detect alleles Q and KNG. Q and KNG
would be considered “positive” alleles, whereas E and TSR
would be considered “negative” alleles for this sample. We
found 158 alleles that were positive both by LDR-FMA and
direct sequencing methods (true positives); 59 alleles were
negative both by LDR-FMA and direct sequencing (true
negatives); 3 alleles were positive by LDR but negative by
direct sequencing (false positives); and 24 alleles were nega-
tive by LDR but positive by direct sequencing (false nega-
tives). Compared with traditional DNA sequencing, the gold
standard, MSP-119 PCR/LDR-FMA had a sensitivity of 87%
and specificity of 95%. Specificity was most affected by the E
allele, and sensitivity was most affected by the TSR allele.
Repeat PCR/LDR-FMA experiments showed 99% concor-
dance, indicating excellent reproducibility.
Pf parasite density by BS, RTQ-PCR, and PCR/LDR-
FMA. Kenyan samples (N  201) were analyzed by micros-
copy, RTQ-PCR and Pf-specific PCR/LDR-FMA (27 cycles)
to compare parasite densities. As expected in a malaria ho-
loendemic area, more children (82%) than adults (34%) were
Pf positive by BS, with parasite densities of 3,740/L blood
(range, 80–48,000) and 148/L blood (range, 80–5,120), re-
spectively. We found 117 of the 201 (58%) samples were
positive by BS. Parasite density as determined by the three
methods showed a positive correlation between increasing
Pf-specific MFI and increasing Pf parasite detection (by BS or
RTQ-PCR; data not shown), which is consistent with previ-
ously published studies.19 As with most nucleic acid detection
methods, PCR-based LDR-FMA is more sensitive than mi-
croscopy for Pf infection detection. Of 84 BS-negative Ken-
yan samples, 24 were positive by Pf LDR-FMA (35 PCR
cycles and MFI cut-off of 3,000) and 37 were positive by Pf
RTQ-PCR (copy number > 10,000). Nineteen of the BS nega-
tive samples were positive by both Pf LDR-FMA and Pf
RTQ-PCR methods.
Relative MSP-119 allele contribution to Pf infection can be
determined with MSP-119 PCR/LDR-FMA. The MSP-119 al-
lele-specific PCR/LDR-FMA was multiplexed with the Pf
specific PCR/LDR-FMA method so that semi-quantitative Pf
infection levels and relative MSP-119 allele contributions to
haplotypes could be determined. Optimal non-saturated PCR
cycling for determining semi-quantitative Pf infection levels
was previously found to be 27 cycles.19 To establish that al-
lele-specific MFIs reflect quantitative differences in their con-
tribution to a mixed strain Pf infections, known amounts of
cultured parasite DNA from strains 3D7 (E-TSR) and K1
(Q-KNG) were combined at various concentrations (i.e.,
3xQ-KNG:1xE-TSR, 2xQ-KNG:1xE-TSR, 1xQ-KNG:1xE-
TSR).20 Twenty-seven cycles of MSP-119–specific PCR/LDR-
FMA were performed, with the results summarized in Figure
2. Figure 2A compares KNG to TSR microspheres with simi-
lar maximum MFIs and shows the expected increase or de-
crease according to the relative amounts of each allele. Figure
2B shows Q versus E microspheres that do not have similar
MFI ranges, and therefore the relative contribution from the
less intense microsphere (Q) appears skewed to the left. How-
ever, if the MFI for Q is adjusted by a factor of 2, the expected
result occurs, and the relative Q:E contributions can be dis-
FIGURE 1. Allele-specific microsphere MFI averaged from 16
separate MSP-119 PCR/LDR-MFA experiments. Controls include
ETSR only, QTSR only, and water. ETSR only represents MSP-119
PCR/LDR-MFA performed with DNA from 3D7 parasites. QKNG
only represents MSP-119 PCR/LDR-MFA performed with DNA
from K1 parasites. A 1:1 combination of 3D7 and K1 parasite DNA
was serially diluted from 1:10 to 1:10,000. The positive threshold for
Q- and E-associated microspheres was set at 800 MFI (dashed hori-
zontal line) and 3,000 MFI for KNG and TSR (solid horizontal line).
The positive threshold for Pf specific associated microsphere was set
at 3,000 MFI. Determination of positive alleles was made using 35-
cycle PCR products.
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cerned (Figure 2C). Thus, the predominant allele can be de-
termined by a stronger relative fluorescence signal in each
mixture. Using Kenyan samples, comparisons of each allele-
specific MFI can be made against Pf-specific semi-
quantitative results. Thus, different FlexMap microsphere in-
tensities can be compared directly to each other (Figure 3).
Using this method, KNG- and TSR-associated microspheres
had comparable fluorescence intensity ranges. Q and E mi-
crospheres did not. E MFIs were approximately twice as in-
tense as Q MFIs. This is consistent with mixed cultured para-
site DNA experiments. Figure 3 also shows positive correla-
tions between allele intensity and Pf MFI, further validating
the semi-quantitative aspect of this method. There was little
variability of allele-specific MFI observed in repeated experi-
ments (data not shown).
Using qualitative and quantitative MSP-119 allele determi-
nation, haplotype assignments were made for each Pf-positive
sample. An example of how haplotype assignments were de-
termined using 35 and 27 PCR cycle products with LDR-
FMA in field samples is shown in Table 2. Twenty-seven-
cycle Q allele MFIs were adjusted as described in Figure 2.
Prevalence and intensity of MSP-119 haplotypes in field
isolates. We used MSP-119–allele specific PCR/LDR-FMA to
evaluate field isolates and found 28% (17) of the samples to
have single haplotype infection, 62% (38) with mixed infec-
tions, and 10% (6) were negative. Single infections contained
only E-KNG or Q-KNG haplotypes. In mixed infections
where two or three alleles were detected, the more prevalent
haplotypes were E-KNG (31) and Q-KNG (30), with E-TSR
(5) and Q-TSR (1) being less common as a co-infecting vari-
ant. Thirteen samples were positive for all four alleles; there-
fore, in these samples, dominant haplotype assignments were
made within each infection using semi-quantitative data
based on the 27 PCR cycle LDR-FMA results with the as-
sumption that only two Pf strains infected an individual at the
sampling time point. Of these 13 samples, haplotype assign-
ment of Q-KNG and E-TSR was made in 8 samples, and
E-KNG and Q-TSR was made in 5 samples. Using this crite-
rion for assigning major haplotype within samples with four
alleles, the overall haplotype prevalence in this study popu-
lation was Q-KNG (38), E-KNG (36), E-TSR (13), and Q-
TSR (6).
Of the 38 samples where three or four alleles were de-
tected, 25 had a clear predominant (major) haplotype and a
subordinant (minor) haplotype when comparing microsphere
intensities after adjusting for the Q allele microsphere with
the lower MFI (Figure 2C). In the mixed infection samples,
the predominant haplotypes were Q-KNG and E-KNG. Q-
TSR was always a minor component of an infection and was
not detected as a single infecting haplotype.
DISCUSSION
MSP-119 allele–specific PCR/LDR-FMA is an inexpensive,
accurate, and high-throughput method well suited for moni-
toring MSP-119 haplotypes in immunoepidemiologic studies
or MSP-1 vaccine efficacy trials. With its excellent sensitivity
and specificity and at 1/10th the cost compared with tradi-
tional DNA sequencing, the MSP-119 PCR/LDR-FMA is a
feasible option for large population-based studies. The
unique feature of this method is that within one multiplexed
FIGURE 2. Relative allele contribution. Known amounts of cul-
tured parasite DNA from strains 3D7 (ETSR) and K1 (QKNG) were
combined at various concentrations (i.e., 3xQKNG:1xETSR,
2xQKNG:1xETSR, 1xQKNG:1xETSR) and measured at 27 cycles of
MSP-119–specific PCR/LDR-FMA. A, MFIs of KNG and TSR mi-
crospheres increase or decrease in direct relation to the relative
amount of each haplotype. B, MFIs of Q and E microspheres do not
increase or decrease in direct relation to the relative amount of each
haplotype in the experimental sample. C, However, if the Q MFI is
doubled, the expected result occurs and the relative Q:E contribu-
tions can be more directly discerned.
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reaction, semi-quantitative Pf infection levels and relative
MSP-119 haplotype contributions can be determined. Estab-
lishing the relative contribution of each MSP-119 haplotype
will allow a more complete understanding of MSP-119 vari-
ability, which may be especially relevant for determining vac-
cine efficacy and immunologic cross-reactivity studies. An-
other advantage of this technique is that it can be expanded to
include other rare MSP-119 haplotypes or other SNPs in genes
of interest. One hundred unique fluorescent microspheres are
available that potentially can be multiplexed in a single-tube
reaction. Recently, examination of 22 different SNPs from
three malaria drug resistance genes was multiplexed into one
LDR-FMA reaction.20 This method lends itself to further ex-
pansions to include unique sequences from any Plasmodium,
human, or other species gene of interest that then can be
compared directly.
The concentration of template DNA for amplification or
sequencing has been shown to not affect the determination of
the relative proportion of alleles in mixed infections.14 For
the LDR method, we start with a uniform amount of DNA
extracted from whole blood with varying concentrations of
Plasmodium genomic DNA determined by the parasite infec-
tion density. We found no differences in our MFI threshold
determinations at different levels of parasitemia.
MSP-119 haplotypes have traditionally been discovered us-
ing direct DNA sequencing techniques that have been
adapted to estimate proportions of alleles within an infection
using proportional sequencing.14 The advantage of direct se-
quencing over the PCR/LDR-FMA method is its ability to
detect rare or novel haplotypes. Recently, a novel pyrose-
quencing method has been shown to be able to identify rare
MSP-119 haplotypes in blood samples from Mali.
15 This
method can also determine the relative haplotype contribu-
tion to infection but does not indicate overall Pf infection
levels and is more labor intensive than the MPS-119 PCR/
LDR-FMA method.
Our results show that the E-KNG and Q-KNG haplotypes
are most common in our study population. Prior studies from
nearby regions show similar results21 demonstrating MSP-119
haplotype stability despite its immunologic recognition. MSP-
TABLE 2








haplotypesQ E KNG TSR 2xQ E KNG TSR
A 6301 6541 23627 688 Q/E KNG 4652 2074 16436 524 QKNG EKNG
B 6228 16785 25018 935 Q/E KNG 4834 6051 17375 508 QKNG/EKNG
C 5680 3916 19060 3237 Q/E KNG/TSR 4444 1424 12162 1802 QKNG ETSR
Thirty-five-cycle MFI in bold indicates positive alleles. Major vs. minor allelic contributions to haplotype assignments were determined using 27-cycle MFI. An adjusted 27-cycle Q allele MFI
(designated 2xQ) as described in Figure 2 and Results was used. In sample A, Q, E, and KNG alleles are positive (35 cycles). The Q allele contribution to infection is greater than the E allele
contribution, thus determining the haplotype assignment of QKNG > EKNG. Conversely, in sample B, a predominant haplotype cannot be inferred as the 27-cycle comparative MFIs because
Q and E are too similar. In sample C, all four alleles are positive. Assuming a two-strain infection, Q and KNG alleles have the highest MFI and are therefore assigned as the major haplotype.
E and TSR have lesser MFI and are assigned as the minor haplotype.
FIGURE 3. Relative MFI of comparative Luminex microspheres for each allele tested using Kenyan samples. An arbitrary dashed line was
drawn intersecting the Q and E allele MFI axes showing the relative differences in MFI for each microsphere: a “Q” MFI of 2,000 was equivalent
to an “E” MFI of 5,000. Using this comparative scale, the relative contribution of each allele to the Pf infection was determined. In contrast, the
KNG- and TSR-associated microspheres had a similar MFI range, and therefore direct comparisons of relative intensity could be made. A positive
correlation between allele MFI and Pf MFI can be observed.
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142 vaccine trials ongoing in this region use the MSP-142 3D7
(E-TSR) variant.22 It is unclear whether immunity is haplo-
type specific underscoring the need to investigate parasite
genetics in conjunction with vaccine and immunologic studies.
The haplotype-specific PCR/LDR-FMA technique is ideal for
such studies.
Additionally, the MSP-119 PCR/LDR-FMA assay is more
sensitive than BS for detecting Pf infection. To understand
the kinetics of infection, immunologic pressures on haplotype
frequency and individual susceptibility to clinical disease, ac-
curate detection and quantification of infection must be un-
derstood. High-throughput methods are essential for large
population-based studies of malaria needed to understand
these complex interactions.
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